Table 1 Patient characteristics (detailed data on patients in subgroups related to TP53 status and the chemotherapy type, as well as the number of patients at risk of recurrence and death in each subgroup at different follow-up points).

Chemotherapy

PC/PAC

TP

PC/PAC

TP

PC/PAC

TP

N = 253

N = 199

N = 104

N = 82

N = 149

N = 117

Age

   Range

24–77

20–78

24–76

20–74

25–77

33–78

   mean (st.dev.)

53.9 (10.6)

54.6 (11.2)

53 (11.3)

55 (11.8)

54.5 (10.1)

54.4 (10.8)

FIGO stage

   IIB, IIC

18 (7%)

10 (5%)

6 (6%)

6 (7%)

12 (8%)

4 (3%)

   IIIA, IIIB

56 (22%)

28 (14%)

23 (22%)

10 (12%)

33 (22%)

18 (15%)

   IIIC

145 (57%)

141 (71%)

60 (58%)

61 (74%)

86 (58%)

80 (68%)

   IV

33 (13%)

20 (10%)

15 (14%)

5 (6%)

18 (12%)

15 (13%)

Residual Tumor Size

   0

53 (21%)

37 (19%)

18 (17%)

16 (20%)

35 (23%)

21 (18%)

   >0 ≤ 2 cm

65 (26%)

81 (41%)

30 (29%)

35 (43%)

35 (23%)

46 (39%)

   >2 cm

135 (53%)

81 (41%)

56 (54%)

31 (38%)

79 (53%)

50 (43%)

Histological Type

   Serous

199 (79%)

147 (74%)

72 (69%)

58 (71%)

127 (85%)

89 (76%)

   Endometrioid, Clear cell

26 (10%)

13 (7%)

21 (20%)

8 (10%)

5 (3%)

5 (4%)

   Undifferentiated

14 (5%)

21 (10%)

5 (5%)

7 (9%)

9 (6%)

14 (12%)

   Other

14 (5%)

18 (9%)

6 (6%)

9 (11%)

8 (5%)

9 (8%)

Tumor grade

   G2

31 (12%)

26 (13%)

20 (19%)

15 (18%)

11 (7%)

11 (9%)

   G3

158 (62%)

115 (58%)

59 (57%)

44 (54%)

99 (66%)

71 (61%)

   G4

64 (25%)

58 (29%)

25 (24%)

23 (28%)

39 (26%)

35 (30%)

TP53 accumulation

   Negative

104 (41%)

82 (41%)

100%

100%

0

0

   Positive

149 (59%)

117 (59%)

0

0

100%

100%

Response to chemotherapy

   complete remission

135 (53%)

131 (66%)

53 (51%)

51 (62%)

82 (55%)

80 (68%)

   partial remission/no change¹

52 (21%)

62 (32%)

18 (17%)

31 (39%)

34 (23%)

31 (27%)

   progression

66 (26%)

6 (3%)

33 (32%)

0

33 (22%)

6 (5%)

Platinum sensitive

109 (43%)

112 (56%)

46 (44%)

42 (51%)

63 (42%)

70 (60%)

Platinum highly sensitive

43 (17%)

39 (20%)

18 (17%)

12 (15%)

25 (17%)

27 (23%)

Platinum resistant

144 (57%)

87 (44%)

58 (56%)

40 (49%)

86 (58%)

47 (40%)

Follow up time for alive patients

N = 30

N = 85

N = 11

N = 36

N = 19

N = 49

Range (months)

10–195

12.7–88.5

10–195

12.7–88.5

33–173.3

12.8–85.1

median

75.5

36.8

81.1

39.4

74.2

33.4

Number of patients at risk (OS)²

   1 year

212 (84%)

187 (94%)

82 (80%)

78 (95%)

130 (87%)

109 (93%)

   2 years

137 (54%)

132 (74%)

54 (53%)

58 (75%)

83 (56%)

75 (74%)

   3 years

90 (36%)

70 (51%)

38 (38%)

26 (47%)

52 (35%)

44 (53%)

   4 years

61 (26%)

45 (39%)

23 (24%)

18 (39%)

38 (27%)

27 (39%)

   5 years

44 (21%)

28 (31%)

17 (19%)

12 (34%)

27 (22%)

16 (29%)

Follow up for disease-free patients³

N = 23

N = 29

N = 10

N = 10

N = 13

N = 19

Range (months)

8.7–187.3

14.6–80.6

15.2–187.3

14.6–69.3

8.7–164.7

14.8–80.6

median

76.2

38.1

68.6

33.6

82.8

38.2

Number of patients at risk (DFS)²

   1 year

72 (54%)

75 (56%)

33 (62%)

27 (53%)

39 (49%)

48 (59%)

   2 years

43 (33%)

39 (33%)

18 (35%)

12 (27%)

25 (31%)

27 (38%)

   3 years

34 (26%)

23 (26%)

14 (27%)

7 (21%)

20 (25%)

16 (28%)

   4 years

24 (20%)

14 (21%)

11 (23%)

5 (21%)

13 (18%)

9 (21%)

   5 years

17 (17%)

6 (14%)

8 (21%)

2 (11%)

9 (15%)

4 (21%)